Klinikum Wolfsburg

Running trials

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Source

• Recruiting

  Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

  NCT07176312· Phase 2· Source

• Recruiting

  A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  NCT06901531· Phase 3· Source

• Not yet recruiting

  Pre-Operative Treatment in REseCTable COlon CanceR

  NCT06899477· Phase 3· Source

• Recruiting

  Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

  2022-502352-31-00· Phase 3· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Source

• Active, not recruiting

  Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

  NCT05713838· Phase 2· Source

• Recruiting

  Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

  NCT05820841· Phase 3· Source

• Recruiting

  MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

  NCT04111978· Phase 3· Source

• Active, not recruiting

  Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients

  NCT04246684· Phase 3· Source

• Active, not recruiting

  FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failure

  NCT04495088· Phase 3· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Source

• Recruiting

  Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

  NCT03643276· Phase 3· Source

• Active, not recruiting

  International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

  NCT03386734· Source

• Active, not recruiting

  Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147· Phase 3· Source

• Recruiting

  Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

  NCT03188874· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• Childhood cancers1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Ovarian cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· Phase 3· Source

• Terminated

  The PLATON Network

  NCT05489250· Source

• Completed

  PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

  NCT04484636· Source

• Completed

  Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

  NCT04375605· Phase 3· Source

• Completed

  CIRCULATE

  NCT04089631· Phase 3· Source

• Completed

  Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

  NCT03647969· Phase 2· Source